Back pain is common, but inflammatory back pain in a 24-year-old who wakes before dawn stiff, improves after movement, and develops alternating buttock pain is not ordinary mechanical strain. Ankylosing spondylitis and the broader category of axial spondyloarthritis matter because delayed recognition can cost years of function, sleep, work capacity, and, for some patients, spinal mobility.

Writing from the perspective of rheumatology practice in Duluth, Dr. Adam Elisha, DO, approaches these conditions as immune mediated diseases with measurable inflammatory patterns, not simply as “bad backs.” The practical question is how to identify axial disease early enough, confirm it responsibly, and choose treatment that matches objective inflammation and patient goals.

What the terms mean

Axial spondyloarthritis, often abbreviated axSpA, describes inflammatory arthritis centered on the sacroiliac joints and spine. Radiographic axial spondyloarthritis is the form with definite sacroiliac joint damage on plain X-ray; ankylosing spondylitis is the traditional name for this radiographic phenotype. Nonradiographic axSpA has similar symptoms and biology, but X-rays may still look normal. That distinction is about imaging stage, not whether the pain is real.

Early signs that should raise suspicion

The earliest clue is the pattern. Inflammatory back pain usually begins before age 45, develops gradually, persists for at least three months, improves with exercise, and does not improve reliably with rest. Night pain, especially pain that improves after getting up, is a major signal. Alternating buttock pain reflects sacroiliac inflammation. Peripheral arthritis, heel enthesitis, dactylitis, uveitis, psoriasis, or inflammatory bowel disease strengthen the case.

A typical scenario is a college athlete who stops running because mornings are miserable, yet feels looser by lunch. A lumbar MRI ordered for a presumed disc problem is unrevealing. The missing step is asking about inflammatory rhythm, family history, eye inflammation, bowel symptoms, and response to nonsteroidal anti-inflammatory drugs.

Diagnosis is clinical, not a single test

There is no standalone blood test for axial spondyloarthritis. HLA-B27 increases probability, especially in the right clinical setting, but many carriers never develop disease and some patients with axSpA are HLA-B27 negative. C-reactive protein and erythrocyte sedimentation rate can support inflammation, but normal values do not exclude active disease.

Imaging is equally nuanced. Pelvic X-ray can show structural sacroiliitis, but early disease may require MRI with short tau inversion recovery or other fluid-sensitive sequences to detect bone marrow edema. The ASAS classification criteria helped standardize research cohorts, yet classification criteria are not diagnostic criteria. The diagnosis still depends on pretest probability, exam findings, imaging quality, and exclusion of mimics such as infection, fracture, malignancy, or degenerative disease.

A common misconception: a normal X-ray rules it out

This misconception is one reason diagnosis is often delayed. Radiographic changes may take years. Conversely, MRI inflammation must be interpreted carefully because mild sacroiliac edema can occur after childbirth, heavy athletic loading, or mechanical stress. Good rheumatology assessment does not “treat the MRI”; it integrates the image with the patient’s inflammatory story.

Treatment goals and first steps

The treatment target is not only pain reduction. It is restoration of function, control of inflammation, prevention of avoidable structural progression, and protection of quality of life. ASAS-EULAR recommendations emphasize education, exercise, smoking cessation, physical therapy when needed, and regular assessment of disease activity, commonly with the Bath Ankylosing Spondylitis Disease Activity Index or Ankylosing Spondylitis Disease Activity Score.

Nonsteroidal anti-inflammatory drugs remain first-line pharmacologic therapy for many patients because prostaglandin inhibition can rapidly improve inflammatory spinal pain. The clinical reasoning is straightforward: if symptoms, function, and objective markers improve with an NSAID and risk is acceptable, escalation may not be necessary. Risks, including kidney disease, hypertension, gastrointestinal bleeding, and cardiovascular disease, shape that decision.

When biologic or targeted therapy is appropriate

For persistently active axial disease despite adequate NSAID trials, guidelines support biologic therapy. Tumor necrosis factor inhibitors have the longest evidence base and are particularly useful when recurrent uveitis or inflammatory bowel disease influences drug selection. Interleukin-17 inhibitors, such as secukinumab and ixekizumab, are effective for axial disease and psoriasis; bowel inflammation requires caution. The JAK inhibitor upadacitinib has FDA approval for active ankylosing spondylitis and nonradiographic axial spondyloarthritis in adults with inadequate response to TNF blockade or other qualifying circumstances, with boxed-warning risks considered carefully.

Choice among these drugs is not a ladder of “stronger” options. It is matching mechanism, comorbid disease, infection risk, vaccination status, pregnancy plans, prior drug exposure, insurance realities, and patient preference. Before biologic or JAK inhibitor therapy, clinicians typically screen for tuberculosis, hepatitis B and C when relevant, update vaccines, and define what improvement will mean.

Monitoring response over time

Monitoring should combine patient-reported outcomes, exam, function, inflammatory markers when informative, and imaging only when it answers a specific question. Repeating MRI simply because pain persists can mislead if the pain generator has changed. Conversely, persistent objective inflammation despite therapy should prompt reassessment of adherence, dose timing, diagnosis, and drug mechanism.

Where the field is heading

Current evidence supports earlier recognition, careful MRI use, exercise as foundational therapy, NSAIDs as appropriate first-line medication, and targeted immune therapy for objectively active disease that remains burdensome. Uncertainty remains around predicting which nonradiographic patients will progress, how best to define remission, and whether earlier biologic treatment changes long-term structural outcomes for all patients. The open questions are important, but the direction is clear: axial spondyloarthritis deserves timely, evidence-based evaluation before years of inflammatory back pain become accepted as normal.

For patients and referring clinicians, pattern recognition remains the decisive first diagnostic tool in practice every day.